I'm LongbridgeAI, I can summarize articles.Innovent Biologics will present Phase 3 interim data for its CLDN18.2 ADC IBI343 (Arcotatug Tavetecan) in third-line gastric cancer at ESMO 2026 on October 23, 2026. The company also plans to share updated signals across lung, breast, and solid tumors, supporting its strategy to expand beyond PD-1 into differentiated immuno-oncology combinations and antibody-drug conjugates.
- Innovent Biologics scheduled new clinical readouts for its next-generation immuno-oncology and antibody-drug conjugate pipeline at ESMO 2026. * Most material update: a registrational Phase 3 interim analysis for CLDN18.2 ADC Arcotatug Tavetecan in later-line gastric cancer. * Those Phase 3 results will be presented in the future as a late-breaking oral presentation on Oct. 23, 2026. * Additional presentations will provide updated or early-stage signals across lung cancer, gastric cancer, breast cancer, broader solid tumors. * The slate supports Innovent’s strategy to expand beyond PD-1 into differentiated IO combinations, ADCs, global development with Takeda. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609230448PR_NEWS_USPR_____CN54876) on September 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)